Breaking News

CytRx Appoints Clinical Development VP

By Kristin Brooks | January 17, 2014

Chawla brings 13 years of clinical research experience

Shanta Chawla, M.D. has been appointed vice president of Clinical Development at CytRx Corp. Dr. Chawla has more than 13 years of clinical research, operations, and development experience, with a focus on oncology.
 
Dr. Chawla joins the company from Spectrum Pharmaceuticals, most recently serving as vice president of Clinical R&D, where she selected clinical trial sites and principal investigators, established protocols with the FDA, and prepared FDA filings.
 
“In this new position, Dr. Chawla will play a key role in the management of our upcoming global Phase 3 clinical trial under a Special Protocol Assessment with aldoxorubicin as a second-line treatment for soft tissue sarcomas,” said CytRx executive vice president and chief medical officer Dr. Daniel Levitt. “She has designed and managed large clinical trials in North America and Europe for a range of cancer types, and brings to CytRx a proven ability to meet enrollment targets and work within budget requirements. We are fortunate to have Dr. Chawla join our team as we move into a very exciting and demanding phase of activity.”

Related Compliance:

blog comments powered by Disqus
  • Top 25 Pharma and Biopharma Report

    Top 25 Pharma and Biopharma Report

    July 20, 2015
    (Based on 2014 Sales, in $U.S. Millions)

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important